Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections.
Daiqin ChenXin YunDaiheon LeeJoseph R DiCostanzoOreola DoniniCecilia M ShikumaKaren ThompsonAxel T LehrerLarissa ShimodaJung Soo SukPublished in: Molecular pharmaceutics (2022)
Vaccine hesitancy and the occurrence of elusive variants necessitate further treatment options for coronavirus disease 2019 (COVID-19). Accumulated evidence indicates that clinically used hypertensive drugs, angiotensin receptor blockers (ARBs), may benefit patients by mitigating disease severity and/or viral propagation. However, current clinical formulations administered orally pose systemic safety concerns and likely require a very high dose to achieve the desired therapeutic window in the lung. To address these limitations, we have developed a nanosuspension formulation of an ARB, entirely based on clinically approved materials, for inhaled treatment of COVID-19. We confirmed in vitro that our formulation exhibits physiological stability, inherent drug activity, and inhibitory effect against SARV-CoV-2 replication. Our formulation also demonstrates excellent lung pharmacokinetics and acceptable tolerability in rodents and/or nonhuman primates following direct administration into the lung. Thus, we are currently pursuing clinical development of our formulation for its uses in patients with COVID-19 or other respiratory infections.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- drug delivery
- high dose
- end stage renal disease
- cystic fibrosis
- ejection fraction
- angiotensin converting enzyme
- newly diagnosed
- blood pressure
- chronic kidney disease
- risk assessment
- low dose
- emergency department
- clinical trial
- prognostic factors
- drug induced
- stem cells
- gene expression
- copy number
- randomized controlled trial
- stem cell transplantation
- bone marrow